Letter to Shareholders Jan. 2011

1Letter to shareholders l Jan. 2011 l LetteR tO SHAReHOLDeRS ISSUe 02 - January 2011 Dear Shareholders, the discovery of meganucleases marked a decisive technological breakthrough in the development of biotechnologies. the DNA content of every one of our... More

1Letter to shareholders l Jan. 2011 l LetteR tO SHAReHOLDeRS ISSUe 02 - January 2011 Dear Shareholders, the discovery of meganucleases marked a decisive technological breakthrough in the development of biotechnologies. the DNA content of every one of our cells is highly complex; its function and organization correspond to specific processes, and each modification can have major consequences. Genome engineering applications range from research to the production of biological compounds, encompassing such diverse areas as the improvement of plant species or therapeutic applications for treating genetic diseases, cancers or viral infections. At Cellectis, our strategy for growth and value creation has manifested itself in a forward integration process that has seen progression from protein engineering products (meganucleases) towards genome engineering products (cells for research and production, therapeutic applications, induced stem cells or modified plants). In order to implement this s Less